
    
      PRIMARY OBJECTIVES:

      I. To provide treatment with domperidone to patients >= 16 years of age where, according to
      the investigators' judgment, a prokinetic effect is needed for the relief of gastrointestinal
      (GI) motility disorders.

      OUTLINE:

      Patients receive domperidone orally (PO) thrice daily (TID) or four times daily (QID).
      Treatment continues in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for at least 30 days.
    
  